Benzinga's Top #PreMarket Gainers

shares gained 18.28% to $8.80 in the pre-market trading session following the announcement of

deal.

shares surged 7.76% to $4.58 in pre-market trading after the company reported that the European Commission has designated its Alpha-1 Antitrypsin as an orphan medicinal product to treat Graft-versus-host disease.

shares rose 4.80% to $52.00 in pre-market trading after the company announced its plans to form a joint venture with United Surgical Partners International Inc.

gained 3.25% to $13.99 in pre-market trading after rising 1.80 on Friday.

shares climbed 2.33% to $4.40 in pre-market trading after the company agreed to sell Chromite assets in Canada for $20 million.